• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

PTC Therapeutics

Biogen to Develop Updated Version of Spinraza
Posted inNeuroscience, Pharma & Biotech, Rare/Orphan Diseases

Biogen to Develop Updated Version of Spinraza

January 5, 2022September 8, 2022

Nusinersen for the treatment of spinal muscular atrophy will get a follow-up.

Zolgensma: Gene Therapy That Cure Spinal Muscular Atrophy. The Most Comprehensive Review
Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory

Zolgensma: Gene Therapy That Cure Spinal Muscular Atrophy. The Most Comprehensive Review

April 8, 2021September 8, 2022

Novartis revealed the most expensive drug in the world. And it is amazing.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News